Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company developing antibody therapeutics for immune-mediated diseases. Its pipeline is built through acquisitions and in-licensing, with lead programs budoprutug and CLYM116 aimed at B-cell and APRIL biology across multiple autoimmune indications.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage anti-CD19 monoclonal antibody being developed for immune-mediated diseases.
Anti-APRIL monoclonal antibody licensed for development and commercialization outside Greater China.
Preclinical and clinical work across pMN, ITP, SLE and other immune-mediated indications.
Customers
Climb Bio does not yet sell approved products, so its near-term 'customers' are clinical investigators, trial sites, regulators and future payors rather than end patients. If approved, the commercial buyers would be physicians, hospitals, specialty pharmacies and third-party payors treating patients with immune-mediated diseases. The target end markets are patients with pMN, ITP, SLE and other B-cell driven autoimmune conditions.
They run the company’s studies and generate the data needed to advance budoprutug and CLYM116.
FDA and other agencies evaluate the clinical package and determine whether the candidates can be approved.
Future prescribers for pMN, ITP and SLE if the products reach market; they will choose based on efficacy and safety.
Insurers and government payors will determine coverage and reimbursement, which will shape uptake.
Strategy
The company’s strategy is to build a focused pipeline in immune-mediated diseases using assets with clear biological rationale and defined development paths. It is prioritizing budoprutug in pMN, ITP and SLE while expanding the platform with CLYM116 to broaden its B-cell targeted franchise. Because it has no manufacturing footprint and no commercial revenue, execution depends on clinical progress, licensing economics and access to external capital.
These indications have a strong mechanistic rationale and could validate the lead asset across multiple autoimmune markets.
Adds pipeline depth and diversifies the company beyond a single lead asset.
The company has no product revenue and will need capital to fund trials and commercialization.
Geography
Climb Bio is headquartered in the United States and conducts its development activities through a U.S.-based clinical-stage organization. The company has worldwide rights to budoprutug except oncology, and rights to CLYM116 worldwide outside Greater China, so future commercialization could span multiple regions if approvals are obtained. At present, it has no product sales and no disclosed country-level revenue.
Risks
Climb Bio is exposed to the classic risks of an early-stage biotech: clinical failure, regulatory delay, and the need for repeated capital raises before any product revenue exists. Its commercial opportunity also depends on payer coverage, physician adoption and competition from better or faster-moving autoimmune therapies. Because it relies on third-party CDMOs and has no commercial infrastructure, supply chain, manufacturing and launch execution risks are also material.
- Clinical development failure or delayImpact: CriticalLikelihood: High
Budoprutug and CLYM116 are still in development and may not show sufficient safety or efficacy.
Exposure - Need for additional capitalImpact: HighLikelihood: High
The company has no product revenue and expects continued operating losses, so funding needs are ongoing.
Exposure: Equity dilution or unfavorable financing terms
- Competitive pressure in autoimmune diseaseImpact: HighLikelihood: Low
Large pharma and biotech peers may launch superior or earlier therapies, limiting market share and pricing.
Exposure: Immune-mediated disease markets
- Manufacturing and supply dependence on CDMOsImpact: MediumLikelihood: Medium
The company does not own manufacturing facilities and relies on third parties for clinical and future commercial supply.
Exposure: Nonclinical and clinical supply chain
Accounting
Judgemental itemsThe company estimates CRO and CDMO costs before invoices are received, which can shift quarterly expense recognition.
Impact: Affects operating loss, accrued liabilities and period-to-period comparability
Employee and director awards are used to attract and retain talent at an early-stage biotech.
Impact: Can materially increase non-cash operating expense
Pipeline value depends on clinical progress, so acquired rights may need reassessment if programs stall.
Impact: Could affect intangible assets and future earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
Inmune Bio, Inc.
INMB · Biological Products, (No Diagnostic Substances)
Climb Global Solutions, Inc.
CLMB · Wholesale-Computers & Peripheral Equipment & Software
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Upstream Bio, Inc.
UPB · Pharmaceutical Preparations
Cullinan Therapeutics, Inc.
CGEM · Biological Products, (No Diagnostic Substances)
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Last updated: 24/09/2026